Molecular Determinants of Head and Neck Cancer

360 Pages·2014·5.866 MB·English

by  Barbara Burtness, Erica A. Golemis (eds.)

Current Cancer Research
SeriesEditor
WafikEl-DeiryUniversityofPennsylvaniaSchoolofMedicine,Philadelphia,Pennsylvania,
USA
Forfurthervolumes:
http://www.springer.com/series/7892
Barbara Burtness • Erica A. Golemis
Editors
Molecular Determinants
of Head and Neck Cancer
2123
Editors
BarbaraBurtness EricaA.Golemis
DepartmentofMedicalOncologyand DevelopmentalTherapeuticsProgram
DevelopmentalTherapeuticsProgram FoxChaseCancerCenter
FoxChaseCancerCenter Philadelphia
Philadelphia Pennsylvania
Pennsylvania USA
USA
ISBN978-1-4614-8814-9 ISBN978-1-4614-8815-6(eBook)
DOI10.1007/978-1-4614-8815-6
SpringerNewYorkHeidelbergDordrechtLondon
LibraryofCongressControlNumber:2014933581
© SpringerScience+BusinessMediaNewYork2014
Thisworkissubjecttocopyright.AllrightsarereservedbythePublisher,whetherthewholeorpartofthe
materialisconcerned,specificallytherightsoftranslation,reprinting,reuseofillustrations,recitation,
broadcasting,reproductiononmicrofilmsorinanyotherphysicalway,andtransmissionorinformation
storageandretrieval,electronicadaptation,computersoftware,orbysimilarordissimilarmethodology
nowknownorhereafterdeveloped.Exemptedfromthislegalreservationarebriefexcerptsinconnection
withreviewsorscholarlyanalysisormaterialsuppliedspecificallyforthepurposeofbeingenteredand
executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this
publicationorpartsthereofispermittedonlyundertheprovisionsoftheCopyrightLawofthePublisher’s
location,initscurrentversion,andpermissionforusemustalwaysbeobtainedfromSpringer.Permissions
forusemaybeobtainedthroughRightsLinkattheCopyrightClearanceCenter.Violationsareliableto
prosecutionundertherespectiveCopyrightLaw.
Theuseofgeneraldescriptivenames,registerednames,trademarks,servicemarks,etc.inthispublication
doesnotimply,evenintheabsenceofaspecificstatement,thatsuchnamesareexemptfromtherelevant
protectivelawsandregulationsandthereforefreeforgeneraluse.
Whiletheadviceandinformationinthisbookarebelievedtobetrueandaccurateatthedateofpublication,
neithertheauthorsnortheeditorsnorthepublishercanacceptanylegalresponsibilityforanyerrorsor
omissionsthatmaybemade.Thepublishermakesnowarranty,expressorimplied,withrespecttothe
materialcontainedherein.
Printedonacid-freepaper
SpringerispartofSpringerScience+BusinessMedia(www.springer.com)
Contents
1 Overview:ThePathobiologyofHeadandNeckCancer............. 1
BarbaraBurtnessandEricaA.Golemis
2 Molecular Features andTreatment Modalities of “Classic”Versus
HumanPapillomaVirus-AssociatedHeadandNeckCancer ........ 7
GiannisMountziosandAmandaPsyrri
3 Epidemiology of HPV in Head and Neck Cancer:Variant Strains,
DiscreteProteinFunction ....................................... 23
CamilleC.R.RaginandJeffreyC.Liu
4 EGFR Inhibitors as Therapeutic Agents in Head
andNeckCancer............................................... 55
HanqingLiu,JenniferR.Cracchiolo,TimN.Beck,IlyaG.Serebriiskii
andEricaA.Golemis
5 The Role of HGF/c-MET in Head and Neck Squamous
CellCarcinoma ................................................ 91
TanguyY.Seiwert,TimN.BeckandRaviSalgia
6 Insulin-likeGrowthFactor-1ReceptorsinHeadandNeckCancer... 113
StevenA.RosenzweigandCaseyO.Holmes
7 The PI3K Signaling Pathway in Head and Neck Squamous Cell
Carcinoma .................................................... 131
JasonD.HowardandChristineH.Chung
8 Jak/STATSignalinginHNC..................................... 163
BhavanaS.VangaraandJenniferR.Grandis
9 TGFβRegulatesEMTinHeadandNeckCancer .................. 179
JillM.NeimanandXiao-JingWang
v
vi Contents
10 TheWnt/β-cateninSignalingCircuitryinHeadandNeckCancer... 199
RogerioM.CastilhoandJ.SilvioGutkind
11 HumanPapillomavirus(HPV)-PositiveHeadandNeckCancer
andtheWntSignalingPathway................................. 215
TheodorosRampiasandAmandaPsyrri
12 p53inHeadandNeckCancer .................................. 227
Jong-LyelRohandWayneM.Koch
13 DNADamageProteinsandResponsetoTherapyinHead
andNeckCancer.............................................. 259
RaneeMehraandIlyaG.Serebriiskii
14 HypoxiaandRadioresistanceinHeadandNeckCancer ........... 283
PeiwenKuoandQuynh-ThuLe
15 SequencingHNC:EmergenceofNotchSignaling ................. 303
CurtisR.Pickering,ThomasJ.OwandJeffreyN.Myers
16 GeneExpressioninHNC....................................... 325
MichaelF.OchsandJosephA.Califano
17 Projections:NovelTherapiesforHPV-NegativeCancers
oftheHeadandNeck.......................................... 343
BarbaraBurtness
Index ............................................................ 361
Contributors
Tim N. Beck Developmental Therapeutics Program, Fox Chase Cancer Center,
Philadelphia,PA,USA
PrograminMolecularandCellBiologyandGenetics,DrexelUniversityCollegeof
Medicine,Philadelphia,PA,USA
BarbaraBurtnessDepartmentofMedicalOncologyandDevelopmentalTherapeu-
ticsProgram,FoxChaseCancerCenter,Philadelphia,PA,USA
DevelopmentalTherapeuticsProgram,FoxChaseCancerCenter,Philadelphia,PA,
USA
JosephA.CalifanoDepartmentofOncology,JohnsHopkinsSchoolofMedicine,
Baltimore,MD,USA
DepartmentofOtolaryngology—HeadandNeckSurgery,JohnsHopkinsSchoolof
Medicine,Baltimore,MD,USA
Milton J. Dance Head and Neck Center, Greater Baltimore Medical Center, Balti-
more,MD,USA
RogerioM.CastilhoLaboratoryofEpithelialBiology,DepartmentofPeriodontics
and Oral Medicine, University of Michigan School of Dentistry, AnnArbor, MI,
USA
Christine H. Chung Department of Oncology, Sidney Kimmel Cancer Center,
JohnsHopkinsMedicalInstitute,Baltimore,MD,USA
Jennifer R. Cracchiolo Department of Otolaryngology Head and Neck Surgery,
TempleUniversitySchoolofMedicine,Philadelphia,PA,USA
EricaA.GolemisDevelopmentalTherapeuticsProgram,FoxChaseCancerCenter,
Philadelphia,PA,USA
JenniferR.GrandisDepartmentofOtolaryngology,UniversityofPittsburghSchool
ofMedicine,Pittsburgh,PA,USA
DepartmentsofPharmacology&ChemicalBiology,Eye&EarInstitute,University
ofPittsburghSchoolofMedicine,Pittsburgh,PA,USA
vii
viii Contributors
J.SilvioGutkindOralandPharyngealCancerBranch,NationalInstituteofDental
andCraniofacialResearch,NationalInstitutesofHealth,Bethesda,MD,USA
CaseyO.HolmesDepartmentofCellandMolecularPharmacology&Experimen-
talTherapeuticsandHollingsCancerCenter,MedicalUniversityofSouthCarolina,
CharlestonSC,USA
JasonD.HowardDepartmentofOncology,SidneyKimmelCancerCenter,Johns
HopkinsMedicalInstitute,Baltimore,MD,USA
Wayne M. Koch Department of Otolaryngology-Head and Neck Surgery, Johns
HopkinsUniversitySchoolofMedicine,Baltimore,MD,USA
PeiwenKuoDepartmentofRadiationOncology,StanfordUniversity,Stanford,CA,
USA
Quynh-ThuLeDepartmentofRadiationOncology,StanfordUniversity,Stanford,
CA,USA
Jeffrey C. Liu Department of Otolaryngology, Fox Chase Cancer Center, Temple
University,Philadelphia,PA,USA
Hanqing Liu Developmental Therapeutics Program, Fox Chase Cancer Center,
Philadelphia,PA,USA
Ranee Mehra Department of Medical Oncology, Fox Chase Cancer Center,
Philadelphia,PA,USA
DevelopmentalTherapeuticsProgram,FoxChaseCancerCenter,Philadelphia,PA,
USA
GiannisMountziosUniversityofAthensSchoolofMedicine,Athens,Greece
JeffreyN.MyersDepartmentofHeadandNeckSurgery,TheUniversityofTexas
MDAndersonCancerCenter,Houston,TX,USA
JillM.NeimanDepartmentofPharmacology,UniversityofColoradoDenver,Au-
rora,CO,USA
Michael F. Ochs Department of Mathematics and Statistics, The College of New
JerseyEwing,NJ,USA
DepartmentofOncology,JohnsHopkinsSchoolofMedicine,Baltimore,MD,USA
DepartmentofOtolaryngology—HeadandNeckSurgery,JohnsHopkinsSchoolof
Medicine,Baltimore,MD,USA
Milton J. Dance Head and Neck Center, Greater Baltimore Medical Center, Balti-
more,MD,USA
Thomas J. Ow Department of Otorhinolaryngology-Head and Neck Surgery and
Department of Pathology, Montefiore Medical Center andAlbert Einstein College
ofMedicine,Bronx,NY,USA
Contributors ix
CurtisR.PickeringDepartmentofHeadandNeckSurgery,TheUniversityofTexas
MDAndersonCancerCenter,Houston,TX,USA
AmandaPsyrri2ndDepartmentofInternalMedicine,AttikonHospital, National
KapodistrianUniversityofAthens,Athens,Greece
Camille.C.R.RaginCancerPreventionandControlProgram,FoxChaseCancer
Center,TempleUniversityHealthSystem,Philadelphia,PA,USA
TheodorosRampiasDepartmentofSurgery,SectionofOtolaryngology,YaleUni-
versitySchoolofMedicine,NewHaven,CT,USA
Jong-Lyel Roh Department of Otolaryngology, Asan Medical Center, College of
Medicine,UniversityofUlsan,Seoul,RepublicofKorea
Steven A. Rosenzweig Department of Cell and Molecular Pharmacology & Ex-
perimentalTherapeuticsandHollingsCancerCenter, MedicalUniversityofSouth
Carolina,CharlestonSC,USA
RaviSalgiaTheUniversityofChicagoComprehensiveCancerCenter,ChicagoIL,
USA
Tanguy Y. Seiwert The University of Chicago Comprehensive Cancer Center,
ChicagoIL,USA
Department of Medicine, Section of Hematology/Oncology, The University of
Chicago,ChicagoIL,USA
IlyaG.SerebriiskiiDevelopmentalTherapeuticsProgram,FoxChaseCancerCen-
ter,Philadelphia,PA,USA
Bhavana S. Vangara Department of Otolaryngology, University of Pittsburgh
SchoolofMedicine,Pittsburgh,PA,USA
Xiao-JingWangDepartmentofPathology,UniversityofColoradoDenver,Aurora,
CO,USA
Chapter 1
Overview: The Pathobiology of Head and Neck
Cancer
BarbaraBurtnessandEricaA.Golemis
Abstract Squamouscellcancersarisingintheheadandneck,fromthenasopharynx
tothesubglotticlarynx,arefrequentlydevastatingcancersthatafflictpatientsaround
theworld.Earlystagecancersarereadilycuredwithsurgeryorradiation.Incontrast,
locally advanced or metastatic cancers require morbid multimodality therapy and
nonethelesshavehighrecurrencerates.Asthisbookaddressesthisdifficultdisease,
ithasthreemaingoals.First,itseekstoprovideanintroductiontotheetiologyand
subclasses of squamous cell carcinomas of the head and neck (SCCHNs), in the
contextofhowthesedifferencesaffectprognosis.Second,itattemptstosummarize
thecurrentstateofunderstandingofthegenetic,epigenetic,andproteinexpression
changes associated with the various classes of SCCHN. Third, it seeks to define
potentialtherapeutictargetsforimprovedmanagementofthediseaseinthefuture.
Keywords Headandneckcancer·Humanpapillomavirus·Epidermalgrowthfactor
receptor(EGFR)·DNArepair·Hypoxia·c-MET·Insulingrowthfactorreceptor
(IGF1R)·Notch·Genomics
Squamous cell cancers arising in the head and neck, from the nasopharynx to the
subglotticlarynx,arefrequentlydevastatingcancersthatafflictpatientsaroundthe
world. Earlystagecancersarereadilycuredwithsurgeryorradiation. Incontrast,
locally advanced or metastatic cancers require morbid multimodality therapy and
nonethelesshavehighrecurrencerates.Asthisbookaddressesthisdifficultdisease,
ithasthreemaingoals.First,itseekstoprovideanintroductiontotheetiologyand
subclasses of squamous cell carcinomas of the head and neck (SCCHNs), in the
contextofhowthesedifferencesaffectprognosis.Second,itattemptstosummarize
thecurrentstateofunderstandingofthegenetic,epigenetic,andproteinexpression
B.Burtness((cid:2))
DepartmentofMedicalOncologyandDevelopmentalTherapeuticsProgram,
FoxChaseCancerCenter,333CottmanAvenue,Philadelphia,PA19111,USA
e-mail:[email protected]
E.A.Golemis·B.Burtness
DevelopmentalTherapeuticsProgram,FoxChaseCancerCenter,
333CottmanAvenue,Philadelphia,PA19111,USA
e-mail:[email protected]
B.Burtness,E.A.Golemis(eds.),MolecularDeterminantsofHeadandNeckCancer, 1
CurrentCancerResearch,DOI10.1007/978-1-4614-8815-6_1,
©SpringerScience+BusinessMediaNewYork2014